Instructions for Use
800.456.2255

How to start your patients on AVONEX

When you have a patient who is ready to start on AVONEX, you can prescribe online or download an AVONEX Start Form, complete it, and fax it to 1-855-474-3067.

To prescribe AVONEX, please follow these 3 steps:

1

After discussing AVONEX with your patient, have your patient read the Patient Consent Information and, if interested, sign the indicated areas on the accompanying AVONEX Start Form.

Biogen takes your patient’s confidentiality seriously. While patients are not required to sign the Start Form in order to receive AVONEX, signing both lines will expedite their enrollment in Biogen Support Services, which provides a variety of financial and insurance assistance options to help your patients get started on AVONEX (see eligibility guidelines). In addition, with both signatures Biogen can access your patient’s prescription status should you or your patient need assistance.

2

Complete the rest of the AVONEX Start Form.

Copy both sides of the patient’s medical insurance card and pharmacy benefit card, if available. In some cases, the medical and pharmacy cards may be the same.

3

Give your patient the Instructions for Patients and Patient Consent Information pages.

Then, fax the AVONEX Start Form to 1-855-474-3067. Prescriptions are only valid when received via fax. The Start Form can also be completed online.

Biogen is committed to getting your patients started on therapy as soon as possible. In addition to the AVONEX Start Form, there are a multitude of services available through Biogen Support Services to help ensure a successful start on treatment. Biogen Case Managers (Support Coordinators), who will reach out to your patients once they are prescribed AVONEX, are available Monday-Friday from 8:30 AM to 8:00 PM ET at 1-800-456-2255.

Download Start Form

iAssista

Biogen and iAssist have partnered to support your prescribing preference. If your office prefers printed Start Forms, you may continue to fax them to 1-855-474-3067. If you would like to learn more about e-prescribing AVONEX through iAssist, please visit iAssist.com.

aiAssist is certified by Surescripts®.

If you have any questions or want to learn more about AVONEX, please call 1-800-456-2255.
Get Started

Get your patients started on therapy with the AVONEX Start Form

E-Sign Start Form

Download Start Form
Surround your patients
with care

Biogen Case Managers and Nurse Educators are here to help your patients start and continue on AVONEX

Get support today
Access and Reimbursement

Coverage and copay program for eligible patients

See Access and Reimbursement
Next: Dosing

Indication

AVONEX® (interferon beta-1a) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

CONTRAINDICATIONS

  • AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation
  • The formerly available lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human)

WARNINGS AND PRECAUTIONS

Depression, Suicide, and Psychotic Disorders

  • Patients treated with AVONEX and their caregivers should be advised to report immediately any symptoms of depression, suicidal ideation, and/or psychosis to their prescribing physician. If a patient develops depression or other severe psychiatric symptoms, cessation of AVONEX therapy should be considered. Depression and suicide have been reported to occur with increased frequency in patients receiving AVONEX. Additionally, there have been postmarketing reports of depression, suicidal ideation, and/or development of new or worsening of other pre-existing psychiatric disorders, including psychosis. For some of these patients, symptoms of depression improved upon cessation of AVONEX

Hepatic Injury

  • Severe hepatic injury, including cases of hepatic failure, has been reported rarely in patients taking AVONEX. Asymptomatic elevation of hepatic transaminases has also been reported, and in some patients has recurred upon rechallenge with AVONEX. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of AVONEX used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered prior to starting AVONEX, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury

Anaphylaxis and Other Allergic-Reactions

  • Anaphylaxis has been reported as a rare complication of AVONEX use. Other allergic reactions have included dyspnea, orolingual edema, skin rash and urticaria. Discontinue AVONEX if anaphylaxis or other allergic reactions occur

Injection Site Reactions Including Necrosis

  • Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products, including AVONEX. In controlled clinical trials, injection site reactions (e.g., injection site pain, bruising or erythema) occurred in 18% of patients receiving AVONEX and 13% in the placebo group. These reactions included injection site inflammation (6%), injection site pain (8%), injection site mass (<1%), nonspecific reactions. Injection site abscesses and cellulitis and injection site necrosis have been reported in the postmarketing setting with interferon beta products, including AVONEX. Some cases required treatment with hospitalization for surgical drainage and intravenous antibiotics. Periodically evaluate patient understanding and use of aseptic self-injection techniques and procedures, particularly if injection site necrosis has occurred. Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis. For patients who continue therapy with AVONEX after injection site necrosis has occurred, avoid administration of AVONEX into the affected area until it is fully healed. If multiple lesions occur, change injection site or discontinue therapy until healing occurs

Congestive Heart Failure

  • Patients with pre-existing congestive heart failure should be monitored for worsening of their cardiac condition during initiation of and continued treatment with AVONEX. While beta interferons do not have any known direct cardiac toxicity, during the postmarketing period cases of congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure have been reported in patients without known predisposition to these events, and without other etiologies being established

Decreased Peripheral Blood Counts

  • Decreased peripheral blood counts in all cell lines, including rare pancytopenia and thrombocytopenia, have been reported from postmarketing experience in AVONEX-treated patients

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products, including AVONEX. Cases have been reported several weeks to years after starting interferon beta products. Discontinue AVONEX if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated

Seizures

  • Seizures have been temporally associated with the use of beta interferons in clinical trials and postmarketing safety surveillance. It is not known whether these events were related to the effects of multiple sclerosis alone, to AVONEX, or to a combination of both

Autoimmune Disorders

  • Postmarketing reports of autoimmune disorders of multiple target organs in AVONEX-treated patients included idiopathic thrombocytopenia, hyper- and hypothyroidism, and rare cases of autoimmune hepatitis. If AVONEX-treated patients develop a new autoimmune disorder, consider stopping the therapy

Laboratory Tests

  • In addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests, are recommended during AVONEX therapy. Patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts. Thyroid function should be monitored periodically. If patients have or develop symptoms of thyroid dysfunction (hypo- or hyperthyroidism), thyroid function tests should be performed according to standard medical practice

MOST COMMON SIDE EFFECTS

  • The most commonly reported adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms. Symptoms can include chills, fever, myalgia and asthenia occurring within hours to days following an injection. The most frequently reported adverse reactions resulting in clinical intervention were flu-like symptoms and depression

Reference: 1. AVONEX Prescribing Information. Cambridge, MA: Biogen.

Start AVONEX
Getting started Dosing Support program
Efficacy
AVONEX efficacy Pivotal trials Long-term follow-up studies
Safety
Well-understood safety profile Adverse reactions Managing common side effects Special populations
Access and reimbursement
Access and
reimbursement

©2023 Biogen. All rights reserved. AVX-US-0587 AVX-US-0588 v5 01/23
All trademarks are the property of their respective owners.
For US healthcare professionals only.